Profil
Kasper Roet founded QurAlis Corp., where he worked as Chief Executive Officer & Director and Enclear Therapies, Inc., where he worked as Director.
Aktive Positionen von Kasper Roet
Unternehmen | Position | Beginn |
---|---|---|
QurAlis Corp.
QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Gründer | - |
Enclear Therapies, Inc.
Enclear Therapies, Inc. Pharmaceuticals: MajorHealth Technology Enclear Therapies, Inc. develops and manufactures novel device-based therapies to treat patients. The firm device is developed to treat and halt the progression of neurodegenerative diseases by removing toxic proteins known to drive pathology. The company was founded by Anthony R. DePasqua, Jonathan J. Fleming, Kasper Roet, William B. Gormley and Kevin Eggan and is headquartered in Newburyport, MA. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
QurAlis Corp.
QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Health Technology |
Enclear Therapies, Inc.
Enclear Therapies, Inc. Pharmaceuticals: MajorHealth Technology Enclear Therapies, Inc. develops and manufactures novel device-based therapies to treat patients. The firm device is developed to treat and halt the progression of neurodegenerative diseases by removing toxic proteins known to drive pathology. The company was founded by Anthony R. DePasqua, Jonathan J. Fleming, Kasper Roet, William B. Gormley and Kevin Eggan and is headquartered in Newburyport, MA. | Health Technology |